[HTML][HTML] Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements
T Verma, N Papadantonakis, D Peker Barclift, L Zhang - Cancers, 2024 - mdpi.com
Simple Summary Myelofibrosis refers to fibrosis in the bone marrow associated with certain
bone marrow cancers. It is a characteristic of primary myelofibrosis and may develop later in …
bone marrow cancers. It is a characteristic of primary myelofibrosis and may develop later in …
Excluding JAK2 V617F mutation analysis from the primary immune thrombocytopenia 'diagnosis of exclusion'
SE Langabeer - Blood Coagulation & Fibrinolysis, 2022 - journals.lww.com
1 Bibas M, Biava G, Antinori A. HIV-associated venous thromboembolism. Mediterr J
Hematol Infect Dis 2011; 3: e2011030. 2 Rasmussen LD, Dybdal M, Gerstoft J, Kronborg G …
Hematol Infect Dis 2011; 3: e2011030. 2 Rasmussen LD, Dybdal M, Gerstoft J, Kronborg G …
Characterization of non-driver mutations and identification of different outcomes and treatment strategies based on NGS results in myelofibrosis patients in different …
S Pepe - 2023 - iris.uniroma1.it
Myelofibrosis (MF), a chronic Ph-negative myeloproliferative neoplasm, is a clinically and
genetically heterogeneous disease. Beside driver mutations that represent the hallmark of …
genetically heterogeneous disease. Beside driver mutations that represent the hallmark of …
The Value of AlloHCT in Patients With Blast Phase Myeloproliferative Neoplasms (BP-MPN)
B May - 2023 - ashpublications.org
In recent years, survival outcomes have improved in patients with blast phase (BP)
transformation of myeloproliferative neoplasms (MPNs) who undergo allogeneic …
transformation of myeloproliferative neoplasms (MPNs) who undergo allogeneic …